Combination Chemotherapy in Treating Women With Resected Breast Cancer
NCT00033683
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any tumor cells remaining after surgery. It is not yet known which combination chemotherapy regimen is more effective in treating resected stage I or stage II breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of different combination chemotherapy regimens in treating women who hav... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/06/2009
Locations: U.Z. Gasthuisberg, Leuven, Not set +68 locations
Conditions: Breast Cancer
Register for Updates
Anti-Cytokine Therapy for Vasculitis
NCT00753103
Completed
The purpose of this study is to determine whether Infliximab (monoclonal anti-tumour necrosis factor alpha antibodies) are safe and effective in the treatment of anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/15/2008
Locations: University Hospitals Birmingham NHS Foundation Trust, Birmingham, West Midlands
Conditions: Wegener's Granulomatosis, Renal Limited Vasculitis, Microscopic Polyangiitis
Register for Updates
IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis
NCT00307645
Terminated
The aim of IMPROVE is to define the optimal maintenance therapy for ANCA-associated vasculitides (AASV) by comparing the AZA (standard regimen) with MMF in terms of efficacy, i.e. in preventing relapses. HYPOTHESIS : MMF might be more effective than azathioprine as maintenance drug in AASV patients, reducing by 50% relapse rate, with a same frequency of adverse effects
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/07/2006
Locations: Hopital Cochin, Paris, Not set +1 locations
Conditions: Granulomatosis and Microscopic Polyangiitis and, Renal Limited Vasculitis, ANCA Associated Systemic Vasculitis Including Wegener's
Register for Updates
Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL.
NCT00244127
Unknown
To evaluate the safety and efficacy of R-COMP in elderly patients with advanced aggressive NHL. Myocet (non-pegylated liposomal doxorubicin) replaces conventional doxorubicin in the R-CHOP regimen.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
10/26/2005
Locations: Not set, Paris, Not set +4 locations
Conditions: Aggressive Non-Hodgkin's Lymphoma in the Elderly.
Register for Updates